Cardiff Oncology

Turning the Tide on RAS-Mutated Colorectal Cancer

Cardiff Oncology is a clinical-stage biotechnology company targeting RAS-mutated metastatic colorectal cancer (mCRC) with onvansertib, our oral, highly selective PLK1 inhibitor. RAS-mutated mCRC is among the hardest to treat cancers, and outcomes on current therapy remain poor.

Our aim is to improve outcomes for patients with difficult-to-treat cancers. Onvansertib, our lead product candidate, is being evaluated in combination with FOLFIRI/bevacizumab as a first-line treatment for RAS-mutated metastatic colorectal cancer (mCRC). Onvansertib + FOLFIRI/bev combination has received Fast Track designation from the U.S. Food and Drug Administration for adult patients with KRAS- or NRAS-mutated mCRC. We are presently advancing onvansertib toward a registrational trial in this patient population.